The effects of selective complement and CD14 inhibition on the E. coli-induced tissue factor mRNA upregulation,

O L Brekke1, C Waage, D Christiansen

  • 1Department of Laboratory Medicine, Nordland Hospital, Bodø, N-8092, Norway.

Abstract

Insights

Complement activation, not CD14, primarily drives E. coli-induced tissue factor (TF) mRNA upregulation in human blood. CD14 plays a minor role in monocyte TF expression and plasma TF activity.

Area of Science:

  • Immunology
  • Hematology
  • Microbiology

Background:

  • The complement pathway and CD14 are crucial in inflammation.
  • Their specific roles in E. coli-induced tissue factor (TF) mRNA upregulation, monocyte expression, and activity in human blood are not well understood.

Purpose of the Study:

  • To investigate the relative contributions of complement activation and CD14 to E. coli-induced TF mRNA upregulation, expression, and activity in human whole blood.

Main Methods:

  • Human whole blood with E. coli was treated with complement inhibitors (compstatin, C5aRa) or anti-CD14 antibody.
  • TF mRNA levels were quantified via RT-qPCR.
  • TF expression and activity were assessed by flow cytometry and plasma microparticle analysis.

Main Results:

  • Compstatin significantly reduced E. coli-induced TF mRNA upregulation.
  • C5a receptor antagonist (C5aRa) reduced monocyte TF expression and plasma TF activity.
  • Anti-CD14 had minimal effect alone but a modest additive effect with complement inhibitors.
  • Combined inhibition reduced pro-inflammatory cytokines.

Conclusions:

  • E. coli-induced TF mRNA upregulation is predominantly mediated by complement activation.
  • CD14 plays a secondary role in monocyte TF expression and plasma TF activity in this context.

Related Concept Videos